---
title: "Orchestra BioMed Holdings, Inc. (OBIO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/OBIO.US.md"
symbol: "OBIO.US"
name: "Orchestra BioMed Holdings, Inc."
industry: "Health Care Equipment"
datetime: "2026-05-20T06:15:17.929Z"
locales:
  - [en](https://longbridge.com/en/quote/OBIO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OBIO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OBIO.US.md)
---

# Orchestra BioMed Holdings, Inc. (OBIO.US)

## Company Overview

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company’s flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.orchestrabiomed.com](https://www.orchestrabiomed.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: C (0.44)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 77 / 183 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 1033.89% |  |
| Net Profit YoY | 17.18% |  |
| P/B Ratio | 5.81 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 239522860.00 |  |
| Revenue | 32724000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -189.24% | E |
| Profit Margin | -166.96% | E |
| Gross Margin | 70.91% | A |
| Revenue YoY | 1033.89% | A |
| Net Profit YoY | 17.18% | B |
| Total Assets YoY | 70.46% | A |
| Net Assets YoY | 202.34% | A |
| Cash Flow Margin | 99.25% | C |
| OCF YoY | 1033.89% | A |
| Turnover | 0.41 | C |
| Gearing Ratio | 49.37% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Orchestra BioMed Holdings, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "1033.89%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "17.18%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.81",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "239522860.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "32724000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-189.24%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-166.96%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "70.91%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "1033.89%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "17.18%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "70.46%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "202.34%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "99.25%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "1033.89%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.41",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "49.37%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.36 | 117/183 | - | - | - |
| PB | 5.81 | 107/183 | 462.73 | 6.18 | 5.07 |
| PS (TTM) | 7.32 | 105/183 | 84.16 | 49.12 | 36.11 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Electromed (ELMD.US) | A | B | A | A | B | A |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | C | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | A | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **8**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 63% |
| Overweight | 2 | 25% |
| Hold | 1 | 13% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.00 |
| Highest Target | 20.00 |
| Lowest Target | 9.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/OBIO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/OBIO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/OBIO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/OBIO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**